KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Accumulated Expenses (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Accumulated Expenses for 18 consecutive years, with $36.0 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 35.65% year-over-year to $36.0 million; the TTM value through Mar 2026 reached $36.0 million, up 35.65%, while the annual FY2025 figure was $116.2 million, 7.19% up from the prior year.
  • Accumulated Expenses hit $36.0 million in Q1 2026 for Ionis Pharmaceuticals, down from $116.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $140.1 million in Q4 2022 and bottomed at $18.2 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $78.4 million, with a median of $99.3 million recorded in 2022.
  • Year-over-year, Accumulated Expenses crashed 81.7% in 2023 and then soared 483.96% in 2024.
  • Ionis Pharmaceuticals' Accumulated Expenses stood at $140.1 million in 2022, then plummeted by 51.66% to $67.7 million in 2023, then skyrocketed by 60.11% to $108.4 million in 2024, then increased by 7.19% to $116.2 million in 2025, then tumbled by 68.99% to $36.0 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $36.0 million, $116.2 million, and $99.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.